Why ADMA Biologics, Inc.’s (ADMA) Stock Is Up 17.10%
As of Thursday, November 05, ADMA Biologics, Inc.’s ADMA share price has surged by 17.10%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Tudor Pop
Jenna Brashear
Michael Rose
Jenna Brashear
| Share Statistics | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,921.8 | $203.5 | 61% |
|
| Shares Out (Mil) | 225.8 | 55.2 | 78% |
|
| Institutional Ownership | 97.8% | 93.3% | 75% |
|
| Float (Mil) | 205.2 | 40.4 | 74% |
|
| Beta | 0.66 | 1.05 | 37% |
|
| Avg Daily Volume (000s) | 3,175 | 569 | 87% |
|
| Price Change (52-week) |
(17.5%) | 38.8% | 39% |
|
| Growth | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 64.6% | 13.6% | 97% |
|
| Net Income (5yr) | 31.6% | (10.7%) | 86% |
|
| EPS (5yr) | 21.8% | 15.4% | 71 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.1%) | (15.7%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 3 | |
| Current EPS | $0.230 | $0.805 | $0.937 | |
| Month Ago EPS | $0.243 | $0.797 | $0.943 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.243 | $0.797 | $0.983 | |
| Year/Year Chg | 4.5% | 34.2% | 100.5% | |
| Financials | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $519 | $40 | 41% |
|
| Net Income (TTM) (Mil) | $182 | ($44) | 66% |
|
| EPS (TTM) | $0.788 | ($1.400) | 57% |
|
| Operating Cash Flow (TTM) (Mil) | $141 | ($35) | 55% |
|
| Net Cash Flow (TTM) (Mil) | $63 | $-0 | 72% |
|
| Long-Term Debt (Q1) (Mil) | $197 | $4 | 49% |
|
| Enterprise Value (Q1) (Mil) | $3,009 | $142 | 55% |
|
| Valuation | ADMA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.68 | 1.96 | 88% |
|
| P/E | 17.1 | 16.9 | 49% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.8 | 0.9 | 41% |
|
| Ratios | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 68.5% | 67.6% | 80% |
|
| Net Margin | 35.1% | (50.8%) | 92% |
|
| ROA | 28.0% | (47.0%) | 98% |
|
| ROE | 41.9% | (51.8%) | 92% |
|
| Liabilities to Assets | 40.1% | 29.6% | 31% |
|
| F-Score | 4 | 3 | 33% |
|
ADMA Biologics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors